Jerash Holdings to Report Financial Results for Fiscal 2021 Fourth Quarter and Full Year on Tuesday, June 22, 2021
FAIRFIELD, NJ / ACCESSWIRE / June 15, 2021 / Jerash Holdings (US), Inc. (NASDAQ:JRSH) (the…
FAIRFIELD, NJ / ACCESSWIRE / June 15, 2021 / Jerash Holdings (US), Inc. (NASDAQ:JRSH) (the…
REDWOOD CITY, CA / ACCESSWIRE / June 15, 2021 / Biotricity, Inc. (OTCQB:BTCY), a medical…
NEW YORK, NY / ACCESSWIRE / June 15, 2021 / Optimus Healthcare Services, Inc. (OTC…
DALLAS, TX / ACCESSWIRE / June 15, 2021 / Many investors will tell you that…
Phase 0 trial in ARDS subjects estimated completion by end of 1st QTR 2022FDA indicates…
NORCROSS, GA / ACCESSWIRE / June 15, 2021 / Success is nothing new for the…
CALGARY, AB / ACCESSWIRE / June 15, 2021 / Perisson Petroleum Corp. (the ‘Corporation‘) (TSXV:POG)…
Uplisting to a National Exchange is the Company’s Objective COSTA MESA, CA / ACCESSWIRE /…
FAYETTEVILLE, AR / ACCESSWIRE / June 15, 2021 / Independent film distributor Hannover House, Inc….
Monthly information regarding the total number of voting rights and total number of shares of…
Monthly information regarding the total number of voting rights and total number of shares of…
TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia…
TORONTO, June 15, 2021 (GLOBE NEWSWIRE) — Aleafia Health Inc. (TSX: AH, OTCQX: ALEAF) (“Aleafia…
Quorum of 18.19% on first convening Combined Shareholders Meeting will be reconvened on June 30,…
Quorum of 18.19% on first convening Combined Shareholders Meeting will be reconvened on June 30,…
RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced…
RANCHO CUCAMONGA, Calif., June 15, 2021 (GLOBE NEWSWIRE) — Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) announced…
TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus”…
TORONTO and CHICAGO and MONTREAL, June 15, 2021 (GLOBE NEWSWIRE) — Medexus Pharmaceuticals Inc. (“Medexus”…
Additional Follow-up of First 20 Adult Patients Enrolled Continues to Show Encouraging Efficacy and Tolerability…